Source: International Congress 2019 – Respiratory syncytial virus infections throughout life
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
S. Cunningham (Edinburgh (Scotland), United Kingdom). Development of RSV antiviral treatment: where are we?. International Congress 2019 – Respiratory syncytial virus infections throughout life

Member's Comments

No comment yet.

Related content which might interest you: Development of RSV vaccines: where are we? Source: International Congress 2019 – Respiratory syncytial virus infections throughout life Year: 2019 Antiviral therapy for influenza: latest trial results Source: Virtual Congress 2020 – New developments in pandemic medicine Year: 2020 Influenza: vaccination and treatment Source: Eur Respir J 2001; 17: 1282-1293 Year: 2001 Antiviral drugs: which and when? Source: Annual Congress 2006 - Influenza: from avian flu to pandemia? Year: 2006 Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19 Source: Eur Respir J, 55 (6) 2000858; 10.1183/13993003.00858-2020 Year: 2020 New treatments for RSV and other viruses, including update on vaccines Source: ERS Courses: Paediatric respiratory infections Year: 2019 Influenza vaccination after lung transplantation: does nasal application improve immunological response? Source: Eur Respir J 2001; 18: Suppl. 33, 179s Year: 2001 Can the influenza vaccine response be predicted in COPD patients by clinical parameters? Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Palivizumab: Is it cost effective to extend the vaccination period for patients at risk of severe respiratory syncytial virus infection? Source: Virtual Congress 2021 – Acute and chronic lung infections in children Year: 2021 Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic Source: Eur Respir Monogr 2021; 94: 39-68 Year: 2021 New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018 Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner? Source: Eur Respir J 2011; 38: 246-247 Year: 2011 Immunology underpinning vaccine strategy: what is the risk of reinfection? Source: Virtual Congress 2020 – Management prevention Year: 2020 Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model Source: Eur Respir J 2011; 38: 401-408 Year: 2011 Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Differentiation between pneumococcal and viral pneumonia in children: what is the best combination of nonspecific markers? Source: Eur Respir J 2001; 18: Suppl. 33, 180s Year: 2001 Viral, bacterial or both? Regardless, we need to treat infection in COPD Source: Eur Respir J 2014; 44: 11-13 Year: 2014